University of Colorado Principal Investigators Receive Grants to Target Precision Therapy for Brain Cancers Including Ependymoma & Glioblastoma

University of Colorado Principal Investigators Receive Grants to Target Precision Therapy for Brain Cancers Including Ependymoma & Glioblastoma

Three University of Colorado-based principal investigators received grants from Denver-based Michele Plachy-Rubin Fund in support of brain cancer research. Receiving $40,000 each, Sujatha Venkataraman, PhD; and the teams of Philip Reigan, PhD, and Michael Graner, PhD; and Natalie Serkova, PhD, and Nicholas Foreman, MD, MBChB. Venkataraman will use her grant to research new treatments for ependymoma, a childhood brain tumor that is incurable in a high percentage of cases.

TrialSite offers a brief summary breakdown for the network.

What is the specific challenge with this class of brain tumor?

According to Dr. Venkataraman, the brain cells associated with ependymoma include concentrated amounts of EZHIP, a gene that is associated with rapid tumor growth. As no drug directly targets this particular gene, the University of Colorado investigator shared in a recent press release that they will identify other genes associated with EZHIP.

How will the team probe the cells within the ependymoma tumors?

The team utilizes a highly sensitive technology to examine these cells within the cancerous tumor.

What have they found thus far?

Interestingly, the University of C...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee